Skip to main content
Premium Trial:

Request an Annual Quote

James Mulshine, Nathaniel Berlin, Peter Klemm

Premium
Gene Express has appointed James Mulshine to its scientific advisory board. Mulshine, a former oncologist at the National Cancer Institute, now is associate provost for research at Rush University Medical Center in Chicago. At NCI, he was head of the Intervention Section of the Cell and Cancer Biology Department, Division of Clinical Sciences. He is a member of the American Society of Clinical Oncology, American Association of Cancer Research, International Association for the Study of Lung Cancer, and the American Federation of Clinical Research.
 

 
Nathaniel Berlin, former director of the National Cancer Institute’s division of Cancer Biology and Diagnosis, died this week in Florida at the age of 87, The Washington Post reported. Berlin also started and directed the Northwestern University Cancer Center and he was a professor of oncology and director of what became the Sylvester Comprehensive Cancer Center.
 

 
Predictive Biosciences has named Peter Klemm president and CEO, as well as a director of the company. Klemm previously was CEO of GeneOhm Sciences, and he was CEO of JOMED and senior VP of R&D at Gruennenthal. He also was a senior scientist at Aventis and a post-doctoral fellow at the William Harvey Research Institute.

Filed under

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.